The cardio-cerebrovascular disease is one of the most basic and common diseases that jeopardize human health, with the incidence and fatality rates increasing year by year, bringing a significant burden to the society and economy. Based on the characteristics of cardio-cerebral diseases interacting with each other and co-existing in many ways, as well as the holistic nature of traditional Chinese medicine and the multi-component, multi-target and multi-pathway characteristics of Chinese medicine, single and compound Chinese medicines can better utilize their advantages in the treatment of such diseases. Styrax is a resin secreted by Styrax arborescens of Hamamelidaceae, which has the effects of inducing resuscitation, eliminating filth and relieving pain. Styrax and related compounds, such as Styrax pills, Guanxin Suhe pills, Shexiang Baoxin pills and Shenxiang Suhe pills are widely used in the treatment of cardiovascular and cerebrovascular diseases. By searching related literature of Styrax and its compounds, the mechanism of Styrax single drug and its compounds in the treatment of cardio-cerebrovascular diseases are summerized in this study, in order to provide a reference for future research direction and facilitate the further development and application of related drugs.

1.Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2023 update: a report from the american heart association[J]. Circulation, 2023, 147(8): 93-621. DOI: 10.1161/cir.0000000000001123.

2.Hilkens NA, Casolla B, Leung TW, et al. Stroke[J]. Lancet, 2024, 403(10446): 2820-2836. DOI: 10.1016/S0140-6736(24)00642-1.

3.施铭岗, 佟小光. 心脑血管疾病的“脑心同治”[J]. 中国现代神经疾病杂志, 2024, 24(1): 17-21. [Shi MG, Tong  XG. Synchronous surgical treatment for brain and heart of cardiovascular and cerebrovascular diseases[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(1): 17-21.] DOI: 10.3969/j.issn.1672-6731.2024.01.004.

4.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2019, 47(10): 766-783. DOI: 10.3760/cma.j.issn. 0253-3758.2019.10.003.

5.中国药典2020年版, 一部[S]. 2020: 172.

6.边晶, 张洪义. 苏合香丸古今应用初探[J]. 中医药临床杂志, 2016, 28(6): 875-878. [Bian J, Zhang HY. Study on ancient and modern application of Suhexiang pill[J]. Clinical Journal of Traditional Chinese Medicine, 2016, 28(6): 875-878.] DOI: 10.16448/j.cjtcm.2016.0310.

7.王勇, 黄春. 苏合香丸联合常规治疗对急性脑梗死患者的临床疗效[J]. 中成药, 2024, 46(11): 3878-3881. [Wang  Y, Huang  C. Clinical effect of Suhexiang pill combined with conventional treatment on patients with acute cerebral infarction[J]. Chin Tradit Pat Med, 2024, 46(11): 3878-3881.] DOI: 10.3969/j.issn.1001-1528.2024.11.058.

8.尹桂红, 符会妮, 彭晓燕. 冠心苏合丸联合替格瑞洛治疗冠心病心绞痛的临床研究[J]. 现代药物与临床, 2021, 36(6): 1149-1153. [Yin GH, Fu HN, Peng XY. Clinical study on Guanxin Suhe pills combined with ticagrelor in treatment of angina pectoris of coronary heart disease[J]. Drugs & Clinic, 2021, 36(6): 1149-1153.] DOI: 10.7501/j.issn.1674-5515.2021.06.009.

9.何松, 王良玉, 闫庆凯, 等. 麝香保心丸配合重组人脑利钠肽治疗轻中度急性心肌梗死[J]. 世界中医药, 2023, 18(2): 229-223. [He S, Wang LY, Yan QK, et al. Shexiang Baoxin pill combined with recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction[J]. World Chinese Medicine, 2023, 18(2): 229-223.] DOI: 10.3969/j.issn.1673-7202.2023.02.013.

10.李敬, 孙红春, 豆书梅, 等. 神香苏合丸辅助治疗冠状动脉三支血管病变的临床观察[J]. 中国药房, 2022, 33(6): 735-744. [Li J, Sun HC, Dou SM, et al. Clinical observation of Shenxiang suhe pill in the adjuvant treatment of triple vessel lesion of coronary artery[J]. China Pharmacy, 2022, 33(6): 735-744.] DOI: 10.6039/j.issn.1001-0408.2022.06.15.

11.中国中西医结合学会急救医学专业委员会. 中国急性缺血性脑卒中中西医急诊诊治专家共识[J]. 中华危重病急救医学, 2018, 30(3): 193-197. DOI: 10.3760/cma.j.issn.2095-4352.2018.03.001.

12.《中成药治疗优势病种临床应用指南》标准化项目组. 中成药治疗冠心病临床应用指南(2020年)[J]. 中西医结合心脑血管病杂志, 2021, 19(9): 1409-1435. DOI: 10.12102/j.issn. 1672-1349.2021.09.001.

13.Campbell BCV, Khatri P. Stroke[J]. Lancet, 2020, 396(1): 129-142. DOI: 10.1016/S0140-6736(20)31179-X.

14.Qin C, Yang S, Chu YH, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions[J]. Signal Transduct Target Ther, 2022, 7(1): 215-243. DOI: 10.1038/s41392-022-01064-1.

15.孙作艳, 岳少乾, 唐巍巍, 等. 芳香开窍药对脑卒中保护作用的实验研究进展[J]. 天津中医药, 2018, 35(1): 77-80. [Sun ZY, Yue SQ, Tang WW, et al. Protective effect of aromatic resuscitation drugs on stroke progress in experimental research[J]. Tianjin Journal of Traditional Chinese Medicine, 2018, 35(1): 77-80.] DOI: 10.11656/j.issn.1672-1519.2018.01.20.

16.周敏, 赵培, 朱金墙, 等. 苏合香对大鼠急性局灶性脑缺血损伤的作用初探[J]. 天津中医药, 2015, 32(8): 496-500. [Zhou  M, Zhao P, Zhu JQ, et al. Effects of storax on acute focal cerebral ischemia injury in rats preliminary study on function[J]. Tianjin Journal of Traditional Chinese Medicine, 2015, 32(8): 496-500.] DOI: 10.11656/j.issn.1672-1519.2015.08.14.

17.Kanazawa M, Takahashi T, Ishikawa M, et al. Angiogenesis in the ischemic core: a potential treatment target?[J]. J Cereb Blood Flow Metab, 2019, 39(5): 753-769. DOI: 10.1177/0271678X19834158.

18.周敏, 范祥, 朱金墙, 等. 苏合香早期干预促进大鼠脑缺血后长期神经功能修复[J]. 天津中医药, 2017, 34(9): 621-625. [Zhou  M, Fan X, Zhu JQ, et al. Early intervention of storax promotes long-term neurological function repair after cerebral ischemia in rats[J]. Tianjin Journal of Traditional Chinese Medicine, 2017, 34(9): 621-625.] DOI: 10.11656/j.issn.1672-1519.2017.09.15.

19.Fang J, Wang Z, Miao CY. Angiogenesis after ischemic stroke[J]. Acta Pharmacol Sin, 2023, 44(7): 1305-1321. DOI: 10.1038/s41401-023-01061-2.

20.文静, 王建, 陈念, 等. 苏合香对永久性大脑中动脉栓塞大鼠模型的脑保护及其机制研究[J]. 时珍国医国药, 2017, 28(10): 2305-2308. [Wen J, Wang J, Chen N, et al. Study of cerebral protection and mechanism of Storax against permanent focal cerebral ischemia injury in rats[J]. Lishizhen Medicine and Materia Medica Research, 2017, 28(10): 2305-2308.] DOI: 10.3969/j.issn.1008-0805.2017.10.001.

21.Zhou M, Li D, Li L, et al. Post-stroke treatment of storax improves long-term outcomes of stroke in rats[J]. J Ethnopharmacol, 2021, 280: 114467. DOI: 10.1016/j.jep.2021.114467.

22.Amantea D, Micieli G, Tassorelli C, et al. Rational modulation of the innate immune system for neuroprotection in ischemic stroke[J]. Front Neurosci, 2015, 9: 00147. DOI: 10.3389/fnins.2015.00147.

23.Li L, Yue S, Han R, et al. Storax protected primary cortical neurons from oxygen-glucose deprivation/reoxygenation injury via inhibiting the TLR4/TRAF6/NF-κB signaling pathway[J]. Brain Res, 2022, 1792: 148021. DOI: 10.1016/j.brainres.2022.148021.

24.张金峰, 鲍莎莎, 张晨星, 等. 苏合香丸调节cAMP-PKA信号通路对急性期脑梗死大鼠神经炎症和神经元凋亡的影响 [J]. 现代生物医学进展, 2024, 24(12): 2237-2243. [Zhang  JF, Bao SS, Zhang CX, et al. Effect of Suhexiang pill on regulation the cAMP-PKA signal pathway on neuroinflammation and neuron apoptosis in rats with acute cerebral infarction[J]. Prog Mod Biomed, 2024, 24(12): 2237-2243.] DOI: 10.13241/j.cnki.pmb.2024.12.006.

25.邵帅, 陈彦霖, 地里热巴提·地力木拉提, 等. 麝香保心丸对小鼠缺血性脑卒中的保护作用及机制[J]. 复旦学报(医 学版), 2021, 48(3): 292-299. [Shao S, Chen YL, Dilirebati  D, et al. Protective effect of Shexiang Baoxin pill on ischemic stroke in mice and its mechanism[J]. Fudan University Journal of Medical Sciences, 2021, 48(3): 292-299.] DOI: 10.3969/j.issn.1672-8467.2021.03.002.

26.Nahirney PC, Reeson P, Brown CE. Ultrastructural analysis of blood-brain barrier breakdown in the peri-infarct zone in young adult and aged mice[J]. J Cereb Blood Flow Metab, 2016, 36(2): 1-13. DOI: 10.1177/0271678X15608396.

27.Abdullahi W, Tripathi D, Ronaldson PT. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection[J]. Am J Physiol, 2018, 315(3): 343-356. DOI: 10.1152/ajpcell.00095.2018.

28.Chow BW, Nunez V, Kaplan L, et al. Caveolae in CNS arterioles mediate neurovascular coupling[J]. Nature, 2020, 579(7797): 106-145. DOI: 10.1038/s41586-020-2026-1.

29.Zhou M, Li D, Shen Q, et al. Storax inhibits caveolae-mediated transcytosis at blood-brain barrier after ischemic stroke in rats[J]. Front Pharmacol, 2022, 13: 876235. DOI: 10.3389/fphar.2022.876235.

30.Chamorro A, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation[J]. Lancet Neurol, 2016, 15(8): 869-871. DOI: 10.1016/S1474-4422(16)00114-9.

31.陈明惠, 严苗艺, 陈颖, 等. 葛根异黄酮抗缺血性脑卒中作用机制的研究[J]. 中国临床药理学杂志, 2022, 38(21): 2591-2595. [Chen MH, Yan MY, Chen Y, et al. Study on mechanism of action of puerararia isoflavone against ischemic stroke[J]. The Chinese Journal of Clinical Pharmacology, 2022, 38(21): 2591-2595.] DOI: 10.13699/j.cnki.1001-6821.2022.21.016.

32.刘小菊, 雷新, 张润峰. 氧化应激反应在冠心病发病中的作用研究进展[J]. 岭南心血管病杂志, 2020, 26(5): 615-618. [Liu  XJ, Lei X, Zhang RF. Research progress on the role of oxidative stress in the pathogenesis of coronary heart disease[J]. South China Journal of Cardiovascular Diseases, 2020, 26(5): 615-618.] DOI: 10.3969/j.issn.1007-9688.2020.05.28.

33.陈雨, 林高城, 白亮. 苏合香挥发油对脑缺血再灌注诱导神经细胞损伤的影响[J]. 中成药, 2020, 42(12): 3298-3302. [Chen  Y, Lin GC, Bai L. Effect of Styrax volatile oil on nerve cell injury induced by cerebral ischemia-reperfusion[J]. Chinese Traditional Patent Medicine, 2020, 42(12): 3298-3302.] DOI: 10.3969/j.issn.1001-1528.2020.12.036.

34.Mao R, Zong N, Hu Y, et al. Neuronal death mechanisms and therapeutic strategy in ischemic stroke[J]. Neurosci Bull, 2022, 38(10): 1229-1247. DOI: 10.1007/s12264-022-00859-0.

35.Qin ZS, Zheng Y, Zhou XD, et al. Shexiang Baoxin pill, a proprietary multi-constituent Chinese medicine, prevents locomotor and cognitive impairment caused by brain ischemia and reperfusion injury in rats: a potential therapy for neuropsychiatric sequelae of stroke[J]. Front Pharmacol, 2021, 12: 665456. DOI: 10.3389/fphar.2021.665456.

36.Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019[J]. Lancet Neurol, 2021, 20(10): 795-820. DOI: 10.1016/S1474-4422(21)00252-0.

37.邵帅, 陈彦霖, 地里热巴提·地力木拉提, 等. 麝香保心丸对小鼠蛛网膜下腔出血的保护作用及机制[J]. 南昌大学学报(医学版), 2021, 61(2): 6-12. [Shao S, Chen YL, Dilirebati  D, et al. Protective effect of Shexiang Baoxin pill on subarachnoid hemorrhage in mice and its mechanism[J]. Journal of Nanchang University (Medical Sciences), 2021, 61(2): 6-12.] DOI: 10.13764/j.cnki.ncdm.2021.02.002.

38.单萍, 姚汉云, 王莉, 等. 基于网络药理学和分子对接的苏合香丸治疗缺血性卒中的机制探究[J]. 药物评价研究, 2022, 45(7): 1294-1311. [Shan P, Yao HY, Wang L, et al. Mechanism of Suhexiang pill in treatment of ischemic stroke based on network pharmacology and molecular docking[J]. Drug Eval Res, 2022, 45(7): 1294-1311.] DOI: 10.7501/j.issn.1674-6376.2022.07.011.

39.刘辉, 王姣, 马岱朝, 等. 苏合香丸治疗蛛网膜下腔出血的网络药理学研究[J]. 辽宁中医杂志, 2020, 47(7): 131-136, 223. [Liu H, Wang J, Ma DC, et al. Network pharmacology analysis of Suhexiang pills in treatment of subarachnoid hemorrhage[J]. Liaoning Journal of Traditional Chinese Medicine, 2020, 47(7): 131-136, 223.] DOI: 10.13192/j.issn.1000-1719.2020.07.036.

40.Jensen RV, Hjortbak MV, Bøtker HE. Ischemic heart disease: an update[J]. Semin Nucl Med, 2020, 50(3): 195-207. DOI: 10.1053/j.semnuclmed.2020.02.007.

41.中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 冠心病心脏康复基层指南(2020年)[J]. 中华全科医师杂志, 2021, 20(2): 150-165. DOI: 10.3760/cma.j.cn114798-20201124-01187.

42.中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 稳定性冠心病基层诊疗指南(实践版·2020)[J]. 中华全科医师杂志, 2021, 20(3): 274-280. DOI: 10.3760/cma.j.cn114798-20210120-00080.

43.陈念, 王建, 樊亚梅, 等. 苏合香对大鼠心肌缺血的影响[J]. 中成药, 2019, 41(3): 533-538. [Chen N, Wang J, Fan YM, et al. Effects of Styrax on myocardial ischemia in rats[J]. Chinese Traditional Patent Medicine, 2019, 41(3): 533-538.] DOI: 10.3969/j.issn.1001-1528.2019.03.010.

44.蔡智慧, 郑亚萍. 冠心苏合丸对乳鼠心肌细胞缺血再灌注损伤的作用[J]. 广州中医药大学学报, 2013, 30(5): 722-728, 775. [Cai ZH, Zheng YP. Effect of Guanxin Suhe pills on neonatal rat cardiomyocytes with ischemia-reperfusion injury[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2013, 30(5): 722-728, 775.] DOI: 10.13359/j.cnki.gzxbtcm.2013.05.035.

45.叶健, 汪谞, 席鑫, 等. 麝香保心丸通过调控miR-144-3p/SLC7A11减轻心肌缺血再灌注损伤的实验研究[J]. 中西医结合心脑血管病杂志, 2023, 21(13): 2396-2399. [Ye J, Wang  X, Xi X, et al. Experimental study of Shexiang Baoxin pill on alleviating myocardial ischemia-reperfusion injury by regulating miR-144-3p/SLC7A11[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2023, 21(13): 2396-2399.] DOI: 10.12102/j.issn.1672-1349.2023.13.010.

46.Liu T, Song D, Dong J, et al. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure[J]. Front Physiol, 2017, 8: 238. DOI: 10.3389/fphys.2017.00238.

47.AlQudah M, Hale TM, Czubryt MP. Targeting the renin-angiotensin-aldosterone system in fibrosis[J]. Matrix Biol, 2020, 91-92: 92-108. DOI: 10.1016/j.matbio.2020.04.005.

48.Yan W, Abu-El-Rub E, Saravanan S, et al. Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators[J]. Am J Physiol Heart Circ Physiol, 2019, 317(2): H213-H225. DOI: 10.1152/ajpheart.00065.2019.

49.Xu Z, Lu D, Yuan J, et al. Storax attenuates cardiac fibrosis following acute myocardial infarction in rats via suppression of AT1R-Ankrd1-P53 signaling pathway[J]. Int J Mol Sci, 2022, 23(21): 1-23. DOI: 10.3390/ijms232113161.

50.刘永存, 张旭升, 黄战军, 等. 麝香保心丸对大鼠醛固酮诱导的心肌纤维化的影响[J]. 中西医结合心脑血管病杂志, 2021, 19(23): 4060-4062. [Liu YC, Zhang XS, Huang ZJ, et al. Effect of Shexiang Baoxin pill on aldosterone-induced myocardium in rats effect of fibrosis[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2021, 19(23): 4060-4062.] DOI: 10.12102/j.issn.1672-1349.2021.23.009.

51.郑亚萍, 董立珉. 冠心苏合丸对大鼠心肌梗死后心肌纤维化的预防作用[J]. 中国中医药现代远程教育, 2014, 12(14): 161-162. [Zheng YP, Dong LM. Preventive effect of Guanxin Suhe pill on myocardial fibrosis on rats post myocardial infarction[J]. Chinese Medicine Modern Distance Education of China, 2014, 12(14): 161-162]. DOI: 10.3969/jissn.1672-2779.2014.14.100.

52.Kim H, Park SJ, Park JH, et al. Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach[J]. Exp Mol Med, 2022, 54(8): 1165-1178. DOI: 10.1038/s12276-022-00827-8.

53.李芃琪, 信琪琪, 袁蓉, 等. 麝香保心丸调控冠心病血管新生的研究进展[J]. 中国实验方剂学杂志, 2022, 28(14): 242-253. [Li PQ, Xin QQ, Yuan R, et al. Shexiang Baoxin pills in regulation ofangiogenesis in coronary heart disease: a review[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(14): 242-253.] DOI: 10.13422/j.cnki.syfjx.20220809.

54.黄斐斐, 刘阳, 陈洁, 等. 麝香保心丸通过上调20-HETE调控内皮祖细胞促进心肌梗死大鼠血管新生[J]. 岭南急诊医学杂志, 2016, 21(1): 4-6, 24. [Huang FF, Liu Y, Chen J, et al. Shexiang Baoxin pill promotes angiogenesis after myocardial infarction via 20-HETE regulated-endothelial progenitor cells mobilization in rats[J]. Lingnan Journal of Emergency Medicine, 2016, 21(1): 4-6, 24.] DOI: 10.3969/j.issn.1671-301X.2016.01.002.

55.吴帮卫, 李剑, 金波, 等. 麝香保心丸促血管新生的机制[J]. 中成药, 2018, 40(6): 1384-1388. [Wu BW, Li J, Jin B, et al. Mechanism of Shexiang Baoxin pills in promoting angiogenesis[J]. Chinese Traditional Patent Medicine, 2018, 40(6): 1384-1388.] DOI: 10.3969/j.issn.1008-0805.2017.10.001.

56.王宇, 芶定芬. 苏合香抗心肌缺血模型大鼠的疗效及剂量关系[J]. 中医学报, 2019, 34(257): 2157-2163. [Wang Y, Gou  DF. Relationship between dose and effects of Suhexiang against myocardial ischemia of model rats[J]. Acta Chinese Medicine, 2019, 34(257): 2157-2163.] DOI: 10.16368/j.issn. 1674-8999.2019.10.500.

57.Xu Z, Lu D, Yuan J, et al. Storax, A promising botanical medicine for treating cardio-cerebrovascular diseases: a review[J]. Front Pharmacol, 2021, 12: 785598. DOI: 10.3389/fphar.2021.785598.

58.魏娜, 李思源, 高苑, 等. 麝香保心丸对缺氧复氧心肌细胞的保护作用及凋亡的影响[J]. 天津医药, 2023, 51(5): 460-463. [Wei N, Li SY, Gao Y, et al. Protective effect of Shexiang Baoxin pill on hypoxia-reoxygenation cardiomyocytes and its effect on apoptosis[J]. Tianjin Medical Journal, 2023, 51(5): 460-463.] DOI: 10.11958/20221264.

59.朱晓宇, 刘洪翠, 俞航萍, 等. 神香苏合丸防治心血管疾病的实验研究[J]. 浙江理工大学学报(自然科学版), 2016, 35(4): 630-635. [Zhu XY, Liu HC, Yu HP, et al.Experimental study on prevention and treatment of cardiovascular diseases with Shenxiang Suhe pill[J]. Journal of Zhejiang Sci-Tech University (Natural Sciences), 2016, 35(4): 630-635.] DOI: 10.3969/j.issn.1673-3851.2016.07026.

60.Wei D, Zheng N, Zheng L, et al. Shexiang Baoxin pill corrects metabolic disorders in a rat model of metabolic syndrome by targeting mitochondria[J]. Front Pharmacol, 2018, 9: 00137. DOI: 10.3389/fphar.2018.00137.

61.Lu L, Qin Y, Zhang X, et al. Shexiang Baoxin pill alleviates the atherosclerotic lesions in mice via improving inflammation response and inhibiting lipid accumulation in the arterial wall[J]. Mediators Inflamm, 2019, 2019: 6710759. DOI: 10.1155/2019/6710759.

62.陶彦谷, 李进营, 韦燕妮, 等. 麝香保心丸防治动脉粥样硬化的实验研究[J]. 中药新药与临床药理, 2015, 26(4): 508-511. [Tao YG, Li JY, Wei YN, et al. Experimental study of Shexiang Baoxin pill in preventing and treating atherosclerosis[J]. Traditional Chinese Drug Research and Clinical Pharmacology, 2015, 26(4): 508-511.] DOI: 10.3969/j.issn.1003-9783.2015.04.020.

63.Zhao JH, Zhang L, Liu Y, et al. Effect of Shexiang Baoxin pill in alleviating early hypertensive renal injury in rats[J]. Chin J Integr Med, 2019, 27(1): 47-53. DOI: 10.1007/s11655-019-3162-z.

64.华蓉, 张青海, 唐毅, 等. 香保心丸对自发性高血压大鼠心脏血管新生的影响[J]. 中国临床药理学杂志, 2024, 40(8): 1180-1183. [Hua R, Zhang  QH, Tang Y, et al. Effect of Shexiang Baoxin pill on cardiac angiogenesis in spontaneously hypertensive rats[J]. The Chinese Journal of Clinical Pharmacology, 2024, 40(8): 1180-1183.] DOI: 10.13699/j.cnki.1001-6821.2024.08.019.

65.刘小燕, 王远征, 韩玉. 麝香保心丸对糖尿病大鼠心肌纤维化的影响[J]. 中药药理与临床, 2012, 28(1): 28-31. [Liu XY, Wang  YZ, Han Y. Effect of Shexiangbaoxinwan pill on myocardial fibrosis of diabetic rats[J]. Pharmacology and Clinics of Chinese Materia Medica, 2012, 28(1): 28-31.] DOI: 10.13412/j.cnki.zyyl.2012.01.013.

66.杨翼鹰, 陈伟燕, 孙秀亭, 等. 麝香保心丸通过抑制p38 MAPK和NF-κB信号传导通路表达对抗高糖诱导的心肌细胞损伤 [J]. 中国临床解剖学杂志, 2016, 34(5): 517-527. [Yang JY, Chen WY, Sun XT, et al. Shexiang Baoxin pill protects cardiomyocytes against high glucose-induced injury by inhibiting the p38 MAPK and NF-κB pathway[J]. Chinese Journal of Clinical Anatomy, 2016, 34(5): 517-527.] DOI: 10.13418/j.issn.1001-165x.2016.05.009.

67.Baman JR, Ahmad FS. Heart Failure[J]. JAMA, 2020, 324(10): 1015. DOI: 10.1001/jama.2020.13310.

68.Schwinger RHG. Pathophysiology of heart failure[J]. Cardiovasc Diagn Ther, 2021, 11(1): 263-276. DOI: 10.21037/cdt-20-302.

69.曹芳芳, 李艳芳, 张玲姬, 等. 麝香保心丸对心力衰竭大鼠内皮素1和肾上腺髓质素水平的影响[J]. 中华老年心脑血管病杂志, 2010, 21(5): 448-451. [Cao FF, Li YF, Zhang LJ, et al. Effect of Shexiang Baoxin pill therapy on plasma levels of endothelin-1 and adrenomedullin in rats with heart failure[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2010, 21(5): 448-451.] DOI: 10.13422/j.cnki.syfjx.2011.20.070.

70.黄婧娟, 洪小苏, 徐卫亭, 等. 麝香保心丸对心梗后心衰家兔心肌细胞外间质重构及MMP-9/TIMP-1mRNA表达的影响[J]. 中成药, 2011, 33(7): 1116-1121. [Huang JJ, Hong XS, Xu WT, et al. Effects of heart-protecting musk pill on myocardial interstitium reconstruction and the expression of MMP-9 /TIMP-1mRNA in rabbits with heart failure after myocardial infraction[J]. Chinese Traditional Patent Medicine, 2011, 33(7): 1116-1121.] DOI: 10.3969/j.issn.1001-1528.2011.07.007.

71.曹芳芳, 李艳芳, 刘飞, 等. 麝香保心丸对心肌梗死后心力衰竭大鼠心脏α1及β肾上腺素能受体表达的影响[J]. 首都医科大学学报, 2010, 31(6): 777-783. [Cao FF, Li YF, Liu F, et al. Effects of Shexiangbaoxinwan pills therapy on the expression of Cardiac α1 and β Adrenergic receptors in rats with heart failure induced by myocardial infarction[J]. Journal of Capital Medical University, 2010, 31(6): 777-783.] DOI: 103969/j.issn.1006-7795.2010.06.018.

72.刘飞, 李艳芳, 曹芳芳, 等. 麝香保心丸对心力衰竭大鼠肾脏血管紧张素Ⅱ受体各亚型表达的影响[J]. 首都医科大学学报, 2012, 33(1): 99-102. [Liu F, Li YF, Cao FF, et al. Effect of Shexiangbaoxin pills on expression of renal angiotensin Ⅱ receptor subtypes in rats with heart failure[J]. Journal of Capital Medical University, 2012, 33(01): 99-102.] DOI: 10.3969/j.issn. 1006-7795.2012.01. 020.

73.许明旭, 张志. 麝香保心丸对压力超负荷大鼠心肌纤维化的影响及机制[J]. 中药药理与临床, 2016, 32(3): 128-132. [Xu  MX, Zhang Z. The effects and mechanisms of Shexiangbaoxinwan on myocardial fibrosis in rats with pressure overload[J]. Pharmacology and Clinics of Chinese Materia Medica, 2016, 32(3): 128-132.] DOI: 10.13412/j.cnki.zyyl.2016.03.034.

74.王智聪, 谢彬, 袁星, 等. 基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制[J]. 药学实践与服务, 2023, 41(5): 296-301. [Wang ZC, Xie B, Yuan X, et al. Mechanism of Shexiang Baoxin pill in the treatment of atherosclerosis based on network pharmacology[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(5): 296-301.] DOI: 10.12206/j.issn.2097-2024.202112001.

75.Yu F, Yu Y, Tian S, et al. Quantitative proteomics reveals Shexiang Baoxin pill exerts cardioprotective effects by preserving energy metabolism in a rat model of myocardial infarction[J]. J Ethnopharmacol, 2021, 266: 113460. DOI: 10.1016/j.jep.2020. 113460.

76.Wu G, Chen L, Gu Y, et al. Exploring the mechanism underlying the cardioprotective effect of Shexiang Baoxin pill on acute myocardial infarction rats by comprehensive metabolomics[J]. J Ethnopharmacol, 2020, 259: 113001. DOI: 10.1016/j.jep.2020.113001.